DK0582368T3 - Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet - Google Patents

Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet

Info

Publication number
DK0582368T3
DK0582368T3 DK93304102T DK93304102T DK0582368T3 DK 0582368 T3 DK0582368 T3 DK 0582368T3 DK 93304102 T DK93304102 T DK 93304102T DK 93304102 T DK93304102 T DK 93304102T DK 0582368 T3 DK0582368 T3 DK 0582368T3
Authority
DK
Denmark
Prior art keywords
treatment
nervous system
central nervous
system disorders
alkyl
Prior art date
Application number
DK93304102T
Other languages
Danish (da)
English (en)
Inventor
David Edward Tupper
John Fairhurst
Terrence Michael Hotten
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0582368T3 publication Critical patent/DK0582368T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK93304102T 1992-05-29 1993-05-26 Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet DK0582368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
DK0582368T3 true DK0582368T3 (da) 2001-02-05

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93304102T DK0582368T3 (da) 1992-05-29 1993-05-26 Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet

Country Status (21)

Country Link
EP (1) EP0582368B1 (sh)
JP (1) JP3219541B2 (sh)
CN (1) CN1043994C (sh)
AT (1) ATE198891T1 (sh)
AU (1) AU668159B2 (sh)
CA (1) CA2097016A1 (sh)
CZ (1) CZ282783B6 (sh)
DE (1) DE69329887T2 (sh)
DK (1) DK0582368T3 (sh)
ES (1) ES2153373T3 (sh)
FI (1) FI101538B (sh)
GR (1) GR3035587T3 (sh)
HU (1) HU218278B (sh)
IL (1) IL105827A (sh)
MX (1) MX9303124A (sh)
MY (1) MY109943A (sh)
NO (1) NO305125B1 (sh)
NZ (1) NZ247703A (sh)
PT (1) PT582368E (sh)
RU (1) RU2125574C1 (sh)
TW (1) TW268005B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
WO1997035582A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
JP2000507945A (ja) * 1996-03-25 2000-06-27 イーライ・リリー・アンド・カンパニー 痛みを処置する方法
WO1997035583A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CA2266444C (en) * 1996-09-23 2007-01-09 Eli Lilly And Company Olanzapine dihydrate d
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
ES2669565T3 (es) 2012-08-21 2018-05-28 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ.ベー. オランザピンに対する抗体及びその使用
CA2882597C (en) 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine haptens and use thereof
CA2882563C (en) 2012-08-21 2022-11-29 Eric Hryhorenko Antibodies to risperidone haptens and use thereof
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス,インコーポレイティド パリペリドンに対する抗体及びその使用
CN104837838A (zh) 2012-08-21 2015-08-12 詹森药业有限公司 帕潘立酮半抗原
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
AU2013305895B2 (en) 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
EP2888257B1 (en) 2012-08-21 2017-08-02 Janssen Pharmaceutica NV Haptens of quetiapine for use in immunoassays
EP3933406A3 (en) 2012-08-21 2022-04-20 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
WO2014031603A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone haptens and use thereof
TR201816378T4 (tr) * 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Olanzapin haptenleri.
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ.ベー. クエチアピンに対する抗体及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
DE2641378A1 (de) * 1975-09-24 1977-04-07 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
FI932445A0 (fi) 1993-05-28
CA2097016A1 (en) 1993-11-30
FI101538B1 (fi) 1998-07-15
NO931917L (no) 1993-11-30
HU218278B (en) 2000-07-28
NZ247703A (en) 1995-07-26
HUT66180A (en) 1994-09-28
MX9303124A (es) 1993-11-01
ES2153373T3 (es) 2001-03-01
HU9301579D0 (en) 1993-09-28
FI932445A (fi) 1993-11-30
EP0582368B1 (en) 2001-01-24
TW268005B (sh) 1996-01-11
DE69329887T2 (de) 2001-05-23
GR3035587T3 (en) 2001-06-29
EP0582368A1 (en) 1994-02-09
CN1085903A (zh) 1994-04-27
JP3219541B2 (ja) 2001-10-15
AU668159B2 (en) 1996-04-26
ATE198891T1 (de) 2001-02-15
CZ102493A3 (en) 1993-12-15
NO305125B1 (no) 1999-04-06
RU2125574C1 (ru) 1999-01-27
CN1043994C (zh) 1999-07-07
JPH0687862A (ja) 1994-03-29
PT582368E (pt) 2001-05-31
CZ282783B6 (cs) 1997-10-15
MY109943A (en) 1997-10-31
DE69329887D1 (de) 2001-03-01
NO931917D0 (no) 1993-05-26
IL105827A0 (en) 1993-09-22
FI101538B (fi) 1998-07-15
IL105827A (en) 1997-02-18
AU3980793A (en) 1993-12-02

Similar Documents

Publication Publication Date Title
DK0582368T3 (da) Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
ES2054020T3 (es) Compuestos biologicamente activos.
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
NO821494L (no) Terapeutisk nyttige 1-alkyl-2-aminotetralinderivater
MX9202803A (es) Nuevos compuestos de benzopirano y procedimiento para su preparacion.
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
MX9300875A (es) Procedimiento para la preparacion de compuestos azabiciclicos.
DK0594099T3 (da) Fremgangsmåde til rensning af rå clavulansyre
DE69823240D1 (de) Immunmodulierende arzneimittelzusammenstellung
ATE98230T1 (de) Indolderivate.
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
DE69527854D1 (de) Derivate substituierter amidinonaphthylester
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.
DK0501442T3 (da) 8-Chlor-benzothiazepin-forbindelse til forebyggelse og behandling af følgerne af cerebral nekrose af nerveceller
ES2133095A1 (es) Acidos alquilidenglutaminicos con propiedades farmaceuticas.